Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope

Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope

With cystic fibrosis patients still dying prematurely and only two products currently approved for the treatment of this disease, the market is wide open for new entrants. Not only will novel symptomatic treatments and re-formulations lead to improved treatment paradigms, truly disease-modifying compounds are in late-stage development and will significantly change the market.

Disease background, segmentation and epidemiology of cystic fibrosis in the US and five major European countries

Summary of the drug classes currently used for the treatment of cystic fibrosis lung disease and cystic fibrosis-related pancreatic insufficiency

An overview of unmet needs, the cystic fibrosis pipeline and clinical trial design

In-depth outline of around 85 compounds studied for the treatment of cystic fibrosis by the pharmaceutical industry and academic institutes

It is clear that, although cystic fibrosis only affects around 52,000 patients in the five major European countries and the US, the pipeline is highly active with over 50 pharmaceutical companies involved. As many as 13 of the compounds studied by the pharmaceutical industry are currently in late-stage development.

The promise of gene therapy has yet to materialize, and mutation specific correcting therapy is eagerly anticipated. There are at least four protein repair treatments in clinical development for three different classes of mutations, although it is likely that combination strategies are required in order to enhance their efficacy.

Disease-modifying treatments that are not mutation-specific include alternative chloride channel activators and epithelial sodium channel inhibitors. Compounds in the former class are furthest along in development; however, it is likely that a combination of the two classes will be necessary for full correction of the airway surface liquid.

Understand and capitalize on clinical unmet needs in the market through both lifecycle management of marketed drugs and new product development

Assess the cystic fibrosis pipeline both through background reading and via the interactive Excel-based pipeline summary

Identify physician awareness and perceptions surrounding future treatments and new developments for cystic fibrosis

Publication: 39873
Library Code: DMHC2486
Type: Report
Format: PDF & SlidePack & DataPack
Pages: 232

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions